Search results for "Unstable angina"

showing 10 items of 80 documents

Prognostic and therapeutic implications of dipyridamole stress cardiovascular magnetic resonance on the basis of the ischaemic cascade

2008

To determine the prognostic and therapeutic implications of stress perfusion cardiovascular magnetic resonance (CMR) on the basis of the ischaemic cascade.Single centre study in a teaching hospital in Spain.Dipyridamole stress CMR was performed on 601 patients with ischaemic chest pain and known or suspected coronary artery disease. On the basis of the ischaemic cascade, patients were categorised in C1 (no evidence of ischaemia, n = 354), C2 (isolated perfusion deficit at stress first-pass perfusion imaging, n = 181) and C3 (simultaneous perfusion deficit and inducible wall motion abnormalities, n = 66). CMR-related revascularisation (n = 102, 17%) was defined as the procedure prompted by t…

MaleChest Painmedicine.medical_specialtyPerfusion ImagingVasodilator AgentsPerfusion scanningCoronary Artery DiseaseChest painMagnetic resonance angiographyCoronary artery diseaseInternal medicineMyocardial RevascularizationmedicineHumanscardiovascular diseasesmedicine.diagnostic_testbusiness.industryUnstable anginaDipyridamoleMiddle AgedPrognosismedicine.diseaseDipyridamoleExercise TestCardiologyFemalemedicine.symptomCardiology and Cardiovascular MedicinebusinessPerfusionMagnetic Resonance AngiographyMacemedicine.drugHeart
researchProduct

Guideline-adherence regarding critical time intervals in the German Chest Pain Unit registry

2020

Background: Since 2008, the German Cardiac Society certified 256 Chest Pain Units (CPUs). Little is known about adherence to recommended performance measures in patients with suspected acute coronary syndrome (ACS) presenting to CPUs. We investigated guideline-adherence regarding critical time intervals and selected performance measures in German Chest Pain Units. Methods: From 2008 to 2014, 23,804 consecutive patients with suspected ACS were prospectively enrolled in the Chest Pain Unit registry of the German Cardiac Society. Results: Median time from symptom onset to first medical contact was 2 h in patients with ST-elevation myocardial infarction (STEMI) and 4 h in patients with unstable…

MaleCritical timeMedizinische Fakultät » Universitätsklinikum Essen » Institut für PathophysiologieTime FactorsMedizin030204 cardiovascular system & hematologyCritical Care and Intensive Care MedicineChest painGermanElectrocardiography610 Medical sciences Medicine0302 clinical medicineGermanyProspective StudiesRegistries030212 general & internal medicineNon-ST Elevated Myocardial InfarctionGuideline adherenceGeneral MedicineMiddle AgedHospitalizationlanguageFemaleAcute coronary syndromeGuideline Adherencemedicine.symptomCardiology and Cardiovascular MedicineHospital UnitsChest Painmedicine.medical_specialtyAcute coronary syndromeguideline-adherence61003 medical and health sciencesPercutaneous Coronary Interventiontime intervalsmedicineHumansIn patientddc:610Angina Unstablecardiovascular diseasesAcute Coronary SyndromeAgedbusiness.industryUnstable anginamedicine.diseaseChest Pain Unitlanguage.human_languageEmergency medicineExercise TestST Elevation Myocardial InfarctionTomography X-Ray ComputedbusinessEuropean Heart Journal: Acute Cardiovascular Care
researchProduct

Herpesvirus DNA (Epstein-Barr virus, herpes simplex virus, cytomegalovirus) in circulating monocytes of patients with coronary artery disease

2005

Background -The underlying mechanism of the chronic inflammatory process in atherosclerosis is still unknown. As a possible trigger, several studies in recent years have suggested that different viruses and bacteria are associated with atherosclerotic diseases. Methods - We applied polymerase chain reaction to analyse whether Epstein-Barr virus (EBV), herpes simplex virus (HSV), and cytomegalovirus (CMV) DNA could be detected in CD14 + cells from 184 patients with angiographically documented coronary artery disease (CAD) (74 patients with stable angina (SAP), 51 patients with unstable angina (UAP), and 59 patients with myocardial infarction (Ml)) and from 52 healthy controls. Results - In t…

MaleHerpesvirus 4 HumanMolecular Sequence DataCytomegalovirusCoronary Artery Diseasemedicine.disease_causePolymerase Chain ReactionRisk AssessmentSensitivity and SpecificitySeverity of Illness IndexVirusAngina Pectorislaw.inventionCoronary artery diseaseSex FactorslawHumansSimplexvirusMedicineAngina UnstableCoronary atherosclerosisPolymerase chain reactionAgedProbabilityAnalysis of VarianceBase Sequencebusiness.industryUnstable anginaIncidenceAge FactorsCytomegalovirusGeneral MedicineMiddle AgedPrognosismedicine.diseaseEpstein–Barr virusVirologyHerpes simplex virusCase-Control StudiesDNA ViralImmunologyFemaleCardiology and Cardiovascular MedicinebusinessActa Cardiologica
researchProduct

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome

2015

BACKGROUND: Cardiovascular morbidity and mortality are higher among patients with type 2 diabetes, particularly those with concomitant cardiovascular diseases, than in most other populations. We assessed the effects of lixisenatide, a glucagon-like peptide 1-receptor agonist, on cardiovascular outcomes in patients with type 2 diabetes who had had a recent acute coronary event.METHODS: We randomly assigned patients with type 2 diabetes who had had a myocardial infarction or who had been hospitalized for unstable angina within the previous 180 days to receive lixisenatide or placebo in addition to locally determined standards of care. The trial was designed with adequate statistical power to …

MaleMyocardial InfarctionKaplan-Meier Estimate2700 General MedicineType 2 diabetesAnginachemistry.chemical_compoundTreatment FailureMyocardial infarctionResearch Support Non-U.S. Gov'tHemoglobin AGeneral MedicineAnginaMiddle AgedMulticenter StudyCardiovascular DiseasesRandomized Controlled TrialCardiologyFemalelixisenatideType 2medicine.medical_specialtyAcute coronary syndromeGlycosylated610 Medicine & healthUnstableGlucagon-Like Peptide-1 Receptor11171 Cardiocentro TicinoLixisenatideAcute Coronary Syndrome; Aged; Angina Unstable; Cardiovascular Diseases; Diabetes Mellitus Type 2; Female; Glucagon-Like Peptide-1 Receptor; Hemoglobin A Glycosylated; Humans; Hypoglycemic Agents; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Peptides; Proportional Hazards Models; Treatment FailureInternal medicineJournal ArticleDiabetes MellitusmedicineHumansHypoglycemic AgentsAngina UnstableAcute Coronary SyndromeAgedProportional Hazards ModelsHemoglobin A GlycosylatedUnstable anginabusiness.industrySemaglutideta3121medicine.diseaseDiabetes Mellitus Type 2chemistryMyocardial infarction complicationsPeptidesbusinessNew England Journal of Medicine
researchProduct

Activated thrombin activatable fibrinolysis inhibitor levels are associated with the risk of cardiovascular death in patients with coronary artery di…

2008

Summary. Background: Thrombin activatable fibrinolysis inhibitor (TAFI) attenuates fibrinolysis. Results on the association between TAFI levels and the risk of coronary artery disease (CAD) are inconsistent. Objectives: We investigated the association between TAFI levels and the risk of cardiovascular events in CAD. Patients/Methods: 1668 individuals with angiographically proven CAD at baseline were followed for a median of 2.3 years, as part of the prospective AtheroGene cohort. Fifty-six deaths from cardiovascular (CV) causes and 35 non-fatal CV events were observed. Results: At baseline, three TAFI measurements were available: one evaluating the total amount of TAFI (t-TAFI), one measuri…

MaleRiskCarboxypeptidase B2medicine.medical_specialtymedicine.medical_treatmentCoronary Artery DiseaseCoronary artery diseaseRisk FactorsInternal medicineFibrinolysismedicineHumansMyocardial infarctionAgedProportional Hazards Modelsbusiness.industryUnstable anginaProportional hazards modelHazard ratioHematologyMiddle Agedmedicine.diseaseCarboxypeptidase BDeath Sudden CardiacCohortCardiologyFemalebusinessProtein Cmedicine.drugJournal of Thrombosis and Haemostasis
researchProduct

Glutathione Peroxidase 1 Activity and Cardiovascular Events in Patients With Coronary Artery Disease

2003

Along with superoxide dismutase, glutathione peroxidase 1 is one of the cellular antioxidant enzymes that have a key role in controlling reactive oxygen species. It uses glutathione to reduce hydrogen peroxide to water and lipid peroxides to their respective alcohols. There are suggestions from in vitro and animal studies that these enzymes could protect against atherosclerosis. This prospective study examined the possibility that relatively high activity of antioxidant enzymes protects against cardiovascular events. The study population included 636 patients suspected of having coronary artery disease who were followed for a median period of 4.7 years. Stable angina was present in 510 pati…

MaleRiskmedicine.medical_specialtyGPX1ErythrocytesAntioxidantmedicine.medical_treatmentCoronary Artery DiseaseGastroenterologyCoronary artery diseaseSuperoxide dismutasechemistry.chemical_compoundSex FactorsInternal medicinemedicineHumansProspective StudiesMyocardial infarctionRisk factorAgedchemistry.chemical_classificationAnalysis of VarianceGlutathione PeroxidaseReactive oxygen speciesbiologySuperoxide DismutaseUnstable anginabusiness.industryGlutathione peroxidaseSmokingObstetrics and GynecologyGeneral MedicineGlutathionemedicine.diseaseSurvival AnalysisEndocrinologychemistryCardiovascular Diseasesbiology.proteinFemalebusinessBiomarkersPeroxidaseObstetrical & Gynecological Survey
researchProduct

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients

2017

Item does not contain fulltext BACKGROUND: Bococizumab is a humanized monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and reduces levels of low-density lipoprotein (LDL) cholesterol. We sought to evaluate the efficacy of bococizumab in patients at high cardiovascular risk. METHODS: In two parallel, multinational trials with different entry criteria for LDL cholesterol levels, we randomly assigned the 27,438 patients in the combined trials to receive bococizumab (at a dose of 150 mg) subcutaneously every 2 weeks or placebo. The primary end point was nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina requiring urgent re…

MaleSTATIN THERAPYAnticholesteremic Agents/adverse effectsAntibodieVascular damage Radboud Institute for Health Sciences [Radboudumc 16]Injections Subcutaneous/adverse effects030204 cardiovascular system & hematologyBococizumablaw.inventionPCSK90302 clinical medicineRandomized controlled triallawRisk FactorsGENETIC-VARIANTSCardiovascular DiseaseMonoclonalAnticholesteremic Agent030212 general & internal medicineMyocardial infarctionTreatment FailureHumanizedProprotein Convertase 9/antagonists & inhibitorsMedicine(all)Antibodies; Antibodies Monoclonal Humanized; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol LDL; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Injections Subcutaneous; Lipids; Male; Middle Aged; Proprotein Convertase 9; Risk Factors; Treatment Failure; Medicine (all)Anticholesteremic AgentsMedicine (all)PCSK9 InhibitorsAntibodies; antibodies monoclonal humanized; anticholesteremic agents; cardiovascular diseases; cholesterol LDL; double-blind method; female; follow-up studies; humans; hypercholesterolemia; injections subcutaneous; lipids; male; middle aged; proprotein convertase 9; risk factors; treatment failure; medicine (all)Vascular damage Radboud Institute for Molecular Life Sciences [Radboudumc 16]General MedicineLipidMiddle AgedLipids3. Good healthLDL/bloodMulticenter StudyCholesterolTRIALSCholesterol LDL/bloodCardiovascular DiseasesAntibodies Monoclonal Humanized/adverse effectsanticholesteremic agentsRandomized Controlled Trialsubcutaneouslipids (amino acids peptides and proteins)FemaleProprotein Convertase 9Cardiovascular Diseases/prevention & controlREDUCING LIPIDSHumanmedicine.medical_specialtyanimal structuresInjections SubcutaneousHypercholesterolemiaHypercholesterolemia/drug therapyPlaceboAntibodies Monoclonal HumanizedInjections SubcutaneouAntibodiesLDLInjectionsFollow-Up StudielipidsEVENTS03 medical and health sciencesantibodies monoclonal humanizedDouble-Blind MethodInternal medicinemedicineJournal ArticleHumansComparative StudyMETAANALYSISAlirocumabbusiness.industryUnstable anginaLipids/bloodPCSK9Risk FactorfungiAntibodies/bloodCholesterol LDLta3121medicine.diseaseSurgerycardiovascular diseasesEvolocumabREDUCTIONHumanized/adverse effectsSubcutaneous/adverse effectsbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyFollow-Up Studies
researchProduct

Prognostic information of glycogen phosphorylase isoenzyme BB in patients with suspected acute coronary syndrome.

2012

Early and adequate risk stratification is essential in patients with suspected acute coronary syndrome (ACS). The aim of the present study was to investigate whether glycogen phosphorylase BB (GPBB) could add prognostic information in the context of contemporary sensitive troponin I determination and B-type natriuretic peptide (BNP). Patients with suspected ACS were consecutively enrolled at 3 German study centers from January 2007 through December 2008. Troponin I, GPBB, and BNP were determined at admission. Follow-up information on the combined end point of death, myocardial infarction, revascularization, and hospitalization owing to a cardiovascular cause was obtained 6 months after enro…

Malemedicine.medical_specialtyAcute coronary syndromeChest PainMyocardial InfarctionKaplan-Meier EstimateGlycogen phosphorylase isoenzyme BBChest painRisk AssessmentSensitivity and SpecificitySeverity of Illness IndexCohort StudiesTroponin TGlycogen Phosphorylase Brain FormPredictive Value of TestsInternal medicineTroponin INatriuretic Peptide BrainMedicineHumansMyocardial infarctionAngina UnstableAcute Coronary SyndromeAgedTroponin Tbusiness.industryUnstable anginaHazard ratioMiddle Agedmedicine.diseasePrognosisSurvival AnalysisCase-Control StudiesCardiologyFemalemedicine.symptomCardiology and Cardiovascular MedicinebusinessBiomarkersThe American journal of cardiology
researchProduct

Timing of percutaneous coronary intervention in troponin-negative patients with acute coronary syndrome without persistent ST-segment elevation: prel…

2015

OBJECTIVE Management of acute coronary syndromes without persistent ST-segment elevation (NSTE-ACS) and unstable angina pectoris (UAP) remains challenging. The study aimed to analyze the current management of UAP patients in German chest pain units focussing on the different time lines of invasive strategy. METHODS A total of 1400 UAP patients admitted to a certified chest pain unit were enrolled. Analyses of high-risk criteria with indication for invasive management and of 3-month clinical outcomes were performed by subgrouping UAP patients to immediate and early invasive (<8 hours), early elective invasive (8-24 hours), late elective invasive (24-72 hours) strategy, and without percutaneo…

Malemedicine.medical_specialtyAcute coronary syndromeChest PainTime Factorsmedicine.medical_treatmentOperative TimeChest painCoronary AngiographyElectrocardiographyPatient AdmissionPercutaneous Coronary InterventionInternal medicineGermanyMedicineST segmentHumansRegistriesAcute Coronary SyndromeAgedRetrospective Studiesbusiness.industryUnstable anginaCoronary Care UnitsPercutaneous coronary interventionRetrospective cohort studyMiddle Agedmedicine.diseaseTroponinRegimenTreatment OutcomeConventional PCICardiologyFemalemedicine.symptomCardiology and Cardiovascular MedicinebusinessFollow-Up StudiesCritical pathways in cardiology
researchProduct

The utility of pregnancy-associated plasma protein A for determination of prognosis in a cohort of patients with coronary artery disease.

2015

Background: Pregnancy-associated plasma protein-A (PAPP-A) is discussed as a biomarker representing unstable plaques in coronary artery disease (CAD). Methods: In this study 927 patients with CAD (534 with stable angina and 393 with acute coronary syndrome [ACS]) and 217 patients without CAD and measured PAPP-A levels were included. Follow-up for a median of 5 years was documented. Results: Rising quartiles of PAPP-A concentration had a higher cardiovascular mortality in the overall cohort of patients with CAD (p = 0.002) and the cohort with ACS (p = 0.01). Patients with suspected ACS below the LOD for troponin I but elevated PAPP-A levels had an increased cardiovascular mortality. A cut-o…

Malemedicine.medical_specialtyAcute coronary syndromeClinical BiochemistryCoronary Artery DiseaseKaplan-Meier EstimateCoronary artery diseaseCohort StudiesRisk FactorsInternal medicineDrug DiscoveryTroponin ImedicineHumansPregnancy-Associated Plasma Protein-AAgedbiologybusiness.industryUnstable anginaBiochemistry (medical)Troponin IMiddle Agedmedicine.diseasePrognosisTroponinROC CurveCohortbiology.proteinCardiologyBiomarker (medicine)FemalebusinessBiomarkersCohort studyFollow-Up StudiesBiomarkers in medicine
researchProduct